Prognostic factors for hepatocellular carcinoma recurrence

被引:1
作者
Antonio Colecchia [1 ]
Ramona Schiumerini [1 ]
Alessandro Cucchetti [2 ]
Matteo Cescon [2 ]
Martina Taddia [1 ]
Giovanni Marasco [1 ]
Davide Festi [1 ]
机构
[1] Department of Gastrointestinal Diseases and Internal Medicine, University of Bologna, 40138 Bologna, Italy
[2] Department of General Surgery and Transplants, University of Bologna, 40138 Bologna, Italy
关键词
Percutaneous ethanol injection; Percutaneous radiofrequency ablation; Transarterial chemoembolization; Hepatic resection; Orthotopic liver transplant; Liver biopsy; Liver stiffness measurement; Hepatocellular carcinoma;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
The recurrence of hepatocellular carcinoma,the sixth most common neoplasm and the third leading cause of cancer-related mortality worldwide,represents an important clinical problem,since it may occur after both surgical and medical treatment.The recurrence rate involves 2 phases:an early phase and a late phase.The early phase usually occurs within 2 years after resection;it is mainly related to local invasion and intrahepatic metastases and,therefore,to the intrinsic biology of the tumor.On the other hand,the late phase occurs more than 2 years after surgery and is mainly related to de novo tumor formation as a consequence of the carcinogenic cirrhotic environment.Since recent studies have reported that early and late recurrences may have different risk factors,it is clinically important to recognize these factors in the individual patient as soon as possible.The aim of this review was,therefore,to identify predicting factors for the recurrence of hepatocellularcarcinoma,by means of invasive and non-invasive methods,according to the different therapeutic strategies available.In particular the role of emerging techniques(e.g.,transient elastography)and biological features of hepatocellular carcinoma in predicting recurrence have been discussed.In particular,invasive methods were differentiated from non-invasive ones for research purposes,taking into consideration the emerging role of the genetic signature of hepatocellular carcinoma in order to better allocate treatment strategies and surveillance follow-up in patients with this type of tumor.
引用
收藏
页码:5935 / 5950
页数:16
相关论文
共 79 条
[61]  
Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observation[J] . Masaaki Ebara,Shinichiro Okabe,Kazuhiko Kita,Nobuyuki Sugiura,Hiroyuki Fukuda,Masaharu Yoshikawa,Fukuo Kondo,Hiromitsu Saisho.Journal of Hepatology . 2005 (3)
[62]   Resection and liver transplantation for hepatocellular carcinoma [J].
Llovet, JM ;
Schwartz, M ;
Mazzaferro, V .
SEMINARS IN LIVER DISEASE, 2005, 25 (02) :181-200
[63]   Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation [J].
Ravaioli, M ;
Grazi, GL ;
Ercolani, G ;
Fiorentino, M ;
Cescon, M ;
Golfieri, R ;
Trevisani, F ;
Grigioni, WF ;
Bolondi, L ;
Pinna, AD .
TRANSPLANTATION, 2004, 78 (12) :1780-1786
[64]  
Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature[J] . Lun-Xiu Qin,Zhao-You Tang.Journal of Cancer Research and Clinical Oncology . 2004 (9)
[65]   Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome [J].
Graziadei, IW ;
Sandmueller, H ;
Waldenberger, P ;
Koenigsrainer, A ;
Nachbaur, K ;
Jaschke, W ;
Margreiter, R ;
Vogel, W .
LIVER TRANSPLANTATION, 2003, 9 (06) :557-563
[66]  
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J] . Josep M. Llovet,Jordi Bruix.Hepatology . 2003 (2)
[67]   Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas [J].
Morimoto, O ;
Nagano, H ;
Sakon, M ;
Fujiwara, Y ;
Yamada, T ;
Nakagawa, H ;
Miyamoto, A ;
Kondo, M ;
Arai, I ;
Yamamoto, T ;
Ota, H ;
Dono, K ;
Umeshita, K ;
Nakamori, S ;
Sasaki, Y ;
Ishikawa, O ;
Imaoka, S ;
Monden, M .
JOURNAL OF HEPATOLOGY, 2003, 39 (02) :215-221
[68]  
Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list[J] . Francis Y. Yao,Nathan M. Bass,Bev Nikolai,Timothy J. Davern,Robert Kerlan,Victor Wu,Nancy L. Ascher,John P. Roberts.Liver Transplantation . 2002 (10)
[69]  
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J] . The Lancet . 2002 (9319)
[70]  
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J] . Hiroshi Imamura,Yutaka Matsuyama,Eiji Tanaka,Takao Ohkubo,Kiyoshi Hasegawa,Shinichi Miyagawa,Yasuhiko Sugawara,Masami Minagawa,Tadatoshi Takayama,Seiji Kawasaki,Masatoshi Makuuchi.Journal of Hepatology . 2002 (2)